These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9224380)

  • 61. Stage I nonseminomatous germ cell tumors: the case for management by risk stratification.
    Al Ghamdi AM; Jewett MA
    Can J Urol; 2005 Feb; 12 Suppl 1():62-5; discussion 103-4. PubMed ID: 15780169
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
    Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
    J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
    [TBL] [Abstract][Full Text] [Related]  

  • 63. alpha-Catenin expression pattern and DNA image-analysis cytometry have no additional value over primary histology in clinical stage I nonseminomatous testicular cancer.
    Spermon JR; De Wilde PC; Hanselaar AG; Schaafsma HE; Ruijter TE; Witjes JA; Van Moorselaar RJ
    BJU Int; 2002 Feb; 89(3):278-84. PubMed ID: 11856111
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Risk factors for occult nodal metastasis in clinical T1N0 lung cancer: a negative impact on survival.
    Veeramachaneni NK; Battafarano RJ; Meyers BF; Zoole JB; Patterson GA
    Eur J Cardiothorac Surg; 2008 Mar; 33(3):466-9. PubMed ID: 18249130
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression.
    Zlobec I; Baker K; Minoo P; Jass JR; Terracciano L; Lugli A
    Clin Cancer Res; 2008 Jan; 14(1):143-8. PubMed ID: 18172264
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
    Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
    J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Proliferation index determined by MIB-1 and recurrence in endometrial cancer.
    Geisler JP; Wiemann MC; Zhou Z; Miller GA; Geisler HE
    Gynecol Oncol; 1996 Jun; 61(3):373-7. PubMed ID: 8641618
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Microvascular invasion of testicular nonseminomatous germ cell tumors: implications of separate evaluation of lymphatic and blood vessels.
    Heinzelbecker J; Gross-Weege M; Weiss C; Hörner C; Trunk MJ; Erben P; Haecker A; Bolenz C
    J Urol; 2014 Aug; 192(2):593-9. PubMed ID: 24631105
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Correlation between p-53 expression and clinical resistance in testicular cancer].
    Hanna E; Bodrogi I; Institoris E; Bak M
    Orv Hetil; 1996 Jan; 137(2):59-64. PubMed ID: 8721869
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Quantitative DNA measurement by flow cytometry and image analysis of human nonseminomatous germ cell testicular tumors.
    de Riese W; Walker EB; de Riese C; Ulbright TM; Crabtree WN; Messemer J; Jones JA; Hinkel A; Foster RS; Donohue JP
    Urol Res; 1994; 22(4):213-20. PubMed ID: 7871632
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Predictive value of Ki-67 and argyrophilic nucleolar organizer region staining for lymph node metastasis in gastric cancer.
    Kakeji Y; Korenaga D; Tsujitani S; Haraguchi M; Maehara Y; Sugimachi K
    Cancer Res; 1991 Jul; 51(13):3503-6. PubMed ID: 2054789
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Flow-cytometric and quantitative histologic parameters as prognostic indicators for occult retroperitoneal disease in clinical-stage-I non-seminomatous testicular germ-cell tumors.
    De Riese WT; De Riese C; Ulbright TM; Walker EB; Messemer J; Jones JA; Reister T; Albers P; Allhoff EP; Foster RS
    Int J Cancer; 1994 Jun; 57(5):628-33. PubMed ID: 8194868
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors.
    de Riese WT; Albers P; Walker EB; Ulbright TM; Crabtree WN; Reister T; Foster RS; Donohue JP
    Cancer; 1994 Aug; 74(4):1335-41. PubMed ID: 8055457
    [TBL] [Abstract][Full Text] [Related]  

  • 74. What does the pathology report really mean?
    Ro JY; Amato RJ; Ayala AG
    Semin Urol Oncol; 1996 Feb; 14(1):2-7. PubMed ID: 9132264
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients.
    Roeleveld TA; Horenblas S; Meinhardt W; van de Vijver M; Kooi M; ten Bokkel Huinink WW
    J Urol; 2001 Dec; 166(6):2166-70. PubMed ID: 11696728
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment.
    Leibovitch I; Foster RS; Kopecky KK; Albers P; Ulbright TM; Donohue JP
    J Clin Oncol; 1998 Jan; 16(1):261-8. PubMed ID: 9440751
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evaluation of testicular germ cell tumor proliferation using DNA flow cytometry and nucleolar organizer silver staining.
    Hasegawa S; Okamura K; Shimoji T; Miyake K; Yamakawa Y; Sakamoto H
    Cytometry; 1994 Jan; 15(1):59-63. PubMed ID: 8162826
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study.
    Sesterhenn IA; Weiss RB; Mostofi FK; Stablein DM; Rowland RG; Falkson G; Rivkind SE; Vogelzang NJ
    J Clin Oncol; 1992 Jan; 10(1):69-78. PubMed ID: 1309382
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pathological predictors of metastatic disease in testicular non-seminomatous germ cell tumors: which tumor-node-metastasis staging system?
    Scandura G; Wagner T; Beltran L; Alifrangis C; Shamash J; Berney DM
    Mod Pathol; 2021 Apr; 34(4):834-841. PubMed ID: 33319858
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: a systematic review and meta-analysis.
    Blok JM; Pluim I; Daugaard G; Wagner T; Jóźwiak K; Wilthagen EA; Looijenga LHJ; Meijer RP; Bosch JLHR; Horenblas S
    BJU Int; 2020 Mar; 125(3):355-368. PubMed ID: 31797520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.